Importantly, a pan-DDR inhibitor, DDR1-IN-1 (46), with higher selectivity toward DDR1 than to DDR2, decreased tumor growth in BRAF-mutated human melanoma xenograft models (43). Here, DDR2 is linked to melanoma.